Accessing methadone within Moldovan prisons: Prejudice and myths amplified by peers. by Polonsky, Maxim et al.
Polonsky, M; Azbel, L; Wickersham, JA; Marcus, R; Doltu, S; Gr-
ishaev, E; Dvoryak, S; Altice, FL (2015) Accessing methadone within
Moldovan prisons: Prejudice and myths amplified by peers. The In-
ternational journal on drug policy. ISSN 0955-3959 DOI: 10.1016/j.drugpo.2015.12.016
Downloaded from: http://researchonline.lshtm.ac.uk/2528482/
DOI: 10.1016/j.drugpo.2015.12.016
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
See	discussions,	stats,	and	author	profiles	for	this	publication	at:	https://www.researchgate.net/publication/287972497
Accessing	Methadone	Within	Moldovan	Prisons:
Prejudice	and	Myths	Amplified	by	Peers
ARTICLE		in		THE	INTERNATIONAL	JOURNAL	ON	DRUG	POLICY	·	DECEMBER	2015
Impact	Factor:	3.19	·	DOI:	10.1016/j.drugpo.2015.12.016
READS
20
8	AUTHORS,	INCLUDING:
Lyuba	Azbel
Yale	University
11	PUBLICATIONS			37	CITATIONS			
SEE	PROFILE
Ruthanne	Marcus
Yale	University
79	PUBLICATIONS			4,026	CITATIONS			
SEE	PROFILE
Frederick	Altice
Yale	University
249	PUBLICATIONS			4,983	CITATIONS			
SEE	PROFILE
All	in-text	references	underlined	in	blue	are	linked	to	publications	on	ResearchGate,
letting	you	access	and	read	them	immediately.
Available	from:	Lyuba	Azbel
Retrieved	on:	01	February	2016
Accepted Manuscript
Title: Accessing Methadone Within Moldovan Prisons:
Prejudice and Myths Amplified by Peers
Author: Maxim Polonsky Lyuba Azbel Jeffrey A.
Wickersham Ruthanne Marcus Svetlana Doltu Evgeny
Grishaev Sergey Dvoryak Frederick L. Altice
PII: S0955-3959(15)00369-2
DOI: http://dx.doi.org/doi:10.1016/j.drugpo.2015.12.016
Reference: DRUPOL 1687
To appear in: International Journal of Drug Policy
Received date: 7-10-2015
Revised date: 13-12-2015
Accepted date: 15-12-2015
Please cite this article as: Polonsky, M., Azbel, L., Wickersham, J. A., Marcus, R.,
Doltu, S., Grishaev, E., Dvoryak, S., and Altice, F. L.,Accessing Methadone Within
Moldovan Prisons: Prejudice and Myths Amplified by Peers, International Journal of
Drug Policy (2015), http://dx.doi.org/10.1016/j.drugpo.2015.12.016
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
Page 1 of 17
Ac
ce
pte
d M
an
us
cri
pt
1
Title: Accessing Methadone Within Moldovan Prisons: Prejudice and Myths Amplified
by Peers
Authors: Maxim Polonsky, Ph.D.1
Lyuba Azbel, M.S.2
Jeffrey A. Wickersham, Ph.D.1
Ruthanne Marcus, Ph.D.1
Svetlana Doltu, M.D.3
Evgeny Grishaev, M.D.4
Sergey Dvoryak, M.D., Ph.D.4
Frederick L. Altice, M.D., M.A.1,5
Affiliation: 1 Yale University School of Medicine, Section of Infectious Diseases, New 
Haven, Connecticut, USA
2 London School of Hygiene and Tropical Medicine, London, UK
3 Action for Involvement (AFI), Chisinau, Moldova
4 Ukrainian Institute on Public Health Policy, Kiev, Ukraine
5 Yale University School of Public Health, Division of Epidemiology of Microbial 
Diseases, New Haven, CT, USA
Contact: Frederick L. Altice, M.D., M.A.
Address: 135 College Street, Suite 323
New Haven, CT, USA 06511
Page 2 of 17
Ac
ce
pte
d M
an
us
cri
pt
2
Telephone: +1.203.737.2883
Facsimile: +1.203.737.4051
Funding: This research received funding from the National Institute on Drug Abuse for 
research (R01 DA029910, Altice, PI and R01 DA033679), career development 
(K24 DA017072 for Altice and K01 DA038529 for Wickersham), and the NIH 
Fogarty Research Training Grant (R25 TW009338, Polonsky).  
Keywords: Attitudes, Prisons, Substance Abuse, opioid agonist therapy, methadone, 
harassment, Moldova
Page 3 of 17
Ac
ce
pte
d M
an
us
cri
pt
3
Abstract
Introduction: The volatile HIV epidemic in Moldova, driven primarily by people who inject 
drugs (PWIDs), is concentrated in prisons. Although internationally recommended opioid agonist
therapy (OAT) is available in Moldovan prisons, coverage remains inadequate and ex ansion 
efforts have failed to meet national and international goals.
Methods: To better understand why eligible prisoners are reluctant to initiate OAT, we surveyed
recently released prisoners who met criteria for opioid dependence and compared those who had 
and had not been enrolled in within-prison OAT (N=56) using standardized scales on OAT 
knowledge and attitudes as well as within-prison harassment experiences. 
Results: Knowledge about OAT was similar between both groups, but this knowledge and myths 
about OAT had independent and opposite direct effects on OAT attitudes. Those who were 
enrolled in OAT in prison were significantly more likely to perceive it as an effective form of 
treatment and had more tolerable attitudes toward OAT but were also more likely to have been 
bullied and to express concerns about their personal safety. Prisoners who had not been enrolled 
in OAT were more likely to endorse negative myths about methadone; only one person among 
them intended to receive OAT in the future.
Conclusion: In Moldovan prisons, OAT enrollment and treatment continuation are influenced by 
ideological biases and myths that are largely formed, amplified, and reinforced behaviorally in 
restricted prison settings. Future interventions that expand OAT in prisons should target 
individual-level ideological prejudices and myths, as well as the prison environment.
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1. Introduction
Moldova, a land-locked country of 3 million people in Eastern Europe that borders 
Romania and Ukraine, has rising HIV incidence, especially among people who inject drugs 
(PWID). HIV prevalence in PWIDs is estimated as 28% (UNAIDS, 2014) and criminalization of 
drugs results in PWIDs being concentrated within the criminal justice system, and therefore in 
increased numbers of people living with HIV (PLH) in prisons (Walmsley, 2014). For example, 
HIV prevalence in Moldova is 0.7% nationally, yet 2.7-fold greater (1.9%) among prisoners.
Similar to other countries of the former Soviet Union (FSU), HIV, PWID and incarceration in 
Moldova are syndemic (Dolan et al., 2007). Unless internationally recommended evidence-based 
harm reduction programs like opioid agonist therapies (OAT) with methadone and 
buprenorphine and needle/syringe exchange programs (NSP) are implemented, there is a risk of 
HIV transmission being amplified in prisons, as well as the risks of relapse to drug use and
overdose after release (Dolan et al., 2015).
OAT is internationally recognized as the most effective form of treatment for chronic 
opioid dependence; only methadone is available in Moldova. OAT reduces HIV transmission, 
criminal activity, relapse to drug use, overdose and recidivism (Keen, Rowse, Mathers, 
Campbell, & Seivewright, 2000; Mattick, Breen, Kimber, & Davoli, 2009). For PLH, it improves
access to HIV care, ART adherence, retention in HIV care and viral suppression (Altice, 
Kamarulzaman, Soriano, Schechter, & Friedland, 2010). Despite this wealth of evidence and 
unlike most of Western Europe, Moldova, Armenia and Kyrgyzstan are the only FSU countries 
that have implemented OAT in prisons. Restrictions on OAT expansion in the region are in part 
due to continued and pervasive influence of Russian Federation; where evidence-based harm 
reduction services like needle exchange programs and OAT are viewed as corrupting influences 
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of the West (Wolfe, 2007). Moldova’s harm reduction programs in prisons are progressive 
relative to other countries in the region, where high levels of stigma and prejudice towards OAT 
prevail (Kazatchkine, 2014). Despite a decade of experience with OAT in Moldova, however, 
expansion within prison has been slow, with many eligible patients in prisons and communities 
refusing to enroll. Nationally, only 880 patients are on OAT, with 259 (29.4%) patients enrolled 
in seven prisons where they are tapered off methadone before release (Zabransky et al., 2012). 
OAT scale-up efforts have been thwarted on many fronts in FSU countries, and have 
been influenced more by moral biases and prejudices than by the scientific evidence (Torrens, 
Fonseca, Castillo, & Domingo-Salvany, 2013). Even where the legal framework supports OAT 
expansion, negative attitudes remain a significant barrier to OAT enrollment, while positive 
attitudes promote treatment entry and retention (Peterson et al., 2010). Currently, no data explore
attitudes toward OAT among prisoners in FSU countries, where such attitudes are often 
amplified within prison subcultures where PWIDs are concentrated. 
2. Materials and methods
2.1. Participants
A comparison study of 56 opioid-dependent PWIDs that were recently released from 
prison was conducted to better understand suboptimal OAT enrollment in Moldovan prisons, 
where it is readily available. Eligibility included: 1) age ≥18 years; 2) ICD-10 criteria for opioid 
dependence; and 3) released to communities within the past 3 months where OAT was available 
in both prisons and communities. Participants were recruited from a NGO that provides HIV 
prevention services to current and former prisoners.  Recently released prisoners were assessed 
to avoid within-prison repercussions for participation. OAT group participants (N=29) were 
compared to those in the No OAT group (N=27) because we expected them to differ in their 
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attitudes and within-prison experiences. In June 2014, eligible and consented participants met 
with trained staff in Chisinau and Balti, Moldova’s only two cities that provide OAT where they 
completed an anonymous online survey and were paid ~$10 USD after completion. Institutional 
review boards at Yale University and the Ukrainian Institute on Public Health Policy approved 
the study. 
2.2. Hypotheses
Because current research shows the attitudes toward OAT is negative within the region 
(Polonsky et al., 2015), we anticipated them to be low in Moldova as well.  We expect those who 
have received OAT in prisons to hold higher knowledge about the benefits of OAT, subscribe 
less to myths about OAT, have more positive attitudes toward OAT, and perceive OAT to be 
more effective, relative to PWIDs who have not received OAT during incarceration.  We also 
hypothesized that stigma and negative attitudes toward OAT will translate into different within-
prison experiences for these two groups and we therefore explicitly explored differences in their 
experience with bullying and perceived personal safety. 
2.3. Measures
We hypothesized that those receiving OAT within prison would potentially differ in 
terms of their OAT attitudes and knowledge, as well as harassment experiences. Several 
standardized scales were used., including a 10-item, seven-point Likert-type response instrument 
assessing OST knowledge and attitudes (Sandra A Springer & Bruce, 2008), with higher 
numbers reflecting higher knowledge and positive attitudes. OAT knowledge (α=0.89) used four 
seven-point Likert-type items that measured an individual’s knowledge about the positive effects 
of OAT on other health outcomes.  An example of a knowledge item is “OAT improves 
adherence to HIV medications in HIV-infected, opioid dependent individuals.” OAT attitudes
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(α=0.90), consisted of six items which measured an individual’s favorable attitudes toward OAT
(e.g., “OAT services should be available in the community so that all people who suffer from 
opioid addiction and want substitution therapy can receive it”). Myths about methadone (OAT 
myths, α=0.81) were measured using 10 five-point Likert-type items with higher scores 
indicating stronger beliefs in prevailing myths about methadone (e.g., “methadone is a Western 
conspiracy”).  OAT effectiveness (α=0.79) was measured by four Likert-type items with higher 
scores indicating higher perceived effectiveness of OAT treatment (e.g., “MMT is an effective 
treatment for drug addiction”). Two harassment constructs included being bullied, and perceived 
personal safety. Consequences of being a victim of bullying were measured by five items 
(Bullying, α=0.77) from Responses to Victimization scale (Ireland, 1999), which used a five-
point Likert-type response from 1 “never” to 5 “often” (e.g., “Threaten to harm him/herself”).
Personal Safety (Safety, α=0.78) was measured using a four 5-point Likert-type items with higher 
numbers indicating higher perceived safety (e.g., “One needs to constantly look over his/her 
shoulder”).
We also asked the participants whether they have heard that methadone is not a good 
treatment for drug addiction (yes/no) including the source they might have heard it from:
doctors, narcologists (addiction physicians), family members, other prisoners. Finally, we asked 
the participants to indicate their intention (yes/no) to continue (OAT group) or initiate (No OAT 
group) OAT treatment in the future.  
2.4. Analysis
Analyses were conducted using SPSS, version 22.  We used correlation and multiple 
regression to assess multivariate relationships among the variables. Independent sample t-tests 
were utilized to determine differences between OAT and No OAT groups in attitudinal 
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constructs (OAT attitudes, myths, and effectiveness), OAT knowledge, as well as within-prison 
harassment experiences (bullying and perceived personal safety), and the effect size Cohen’s d
(noted a “d” throughout) for each mean comparison was calculated separately. Non-parametric 
procedures (i.e., chi-square and descriptive statistics) were used to analyze study participants’ 
categorical responses. 
3. Results
The sample consisted of 56 OAT and No OAT participants who did not differ 
demographically: mean age=36 years, female (20%), and unmarried (47%). Table 1 presents 
multiple correlations among the various constructs. While OAT knowledge and attitudes 
correlated with each other, as did the three harassment constructs, there were no relationships
among the attitudinal and harassment variables between the two groups.  OAT knowledge and 
myths both correlated with attitudes but were statistically independent from one another. The 
results of multiple regression with OAT knowledge and myths as predictors and OAT attitudes 
as an outcome produced R2=0.44, F(2,54)=20.11, p<0.01, and revealed that knowledge about
OAT (β=0.43, p<0.01) and myths about OAT (β=-0.40, p<0.01) have had independent opposing 
effects of a similar magnitude on OAT attitudes.
Figure 1A demonstrates differences between OAT and No OAT groups. Aside from OAT 
knowledge (t(55)=0.49, p=0.62), all attitudinal variables differed significantly. Compared to 
PWIDs who didn’t receive within-prison OAT, those who did held more positive attitudes 
(M=4.75, SD=0.68 vs. 3.98, SD=1.69, t(55)=2.27, p<0.05, d=0.59), perceived OAT effectiveness 
to be higher (M=4.60, SD=0.72 vs. M=3.60, SD=1.60, t(54)=3.06, p<0.01, d=0.81), and were 
less likely to endorse myths about OAT (M=2.74, SD=0.80 vs. M=3.24, SD=1.08, t(55)=-2.01, 
p<0.05, d=-0.53). Harassment experiences also differed (Figure 1B). Compared to PWIDs not 
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receiving within-prison OAT, those who did were significantly less likely to report feeling safe 
(M=3.33, SD=1.40 vs. M=4.12, SD=1.37, t(55)=-2.114, p<0.05, d=-0.57) and more likely to 
have been bullied (M=3.43, SD=1.77 vs. M=2.43, SD=1.77, t(55)=2.15, p<0.05), d=0.56).
Nearly two-thirds (65%) had previously heard that methadone was not a “good” 
treatment for addiction (Figure 1C). Among these, most (87%) had heard this from other 
prisoners, while a critical minority had also heard this from physicians (39%) and family 
members (36%). Finally, only one participant in the No OAT group expressed the intention to 
initiate OAT treatment in the future, while five participants in the OAT group expressed the 
desire to discontinue OAT.
4. Discussion
To our knowledge, this is the first study to explore OAT attitudes and harassment 
experiences among prisoners in a FSU country where OAT is readily available within prisons 
and where comparisons can be made between those accessing and not accessing OAT. We found 
that higher knowledge about OAT was associated with positive attitudes toward OAT, echoing 
similar findings among Ukrainian prison personnel, where OAT knowledge was positively 
correlated with OAT attitudes (Polonsky et al., 2015). Importantly and to our surprise, however, 
we found that OAT knowledge and myths had opposing and independent effects on OAT 
attitudes, and that knowledge did not differ between the two groups, but that attitudes toward and 
myths about OAT did. These results imply that knowledge and myths about methadone may
coexist and are not mutually exclusive, and illustrate that ideological origins of attitudes count 
just as much as accurate information. That is, a person may know about the benefits of OAT, and
yet, be prejudiced against it, which is supported by seminal psychological work on attitude 
formation (Zajonc, 1980).
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After a decade of treating and educating prisoners about OAT in Moldova, our findings 
reveal a potential ceiling effect of knowledge-based interventions that do not also focus on 
affective and ideological aspects of prevailing attitudes (Breckler, 1984). It can be argued that 
although PWIDs in Moldova are relatively well-informed about OAT, they are embedded within 
a stigmatizing prison culture that is against it and therefore may be continuously exposed to and 
endorse negative myths about OAT. Similar to being the amplifiers of diseases (Azbel, 
Wickersham, Grishaev, Dvoryak, & Altice, 2013; S.A. Springer & Altice, 2007), prisons may 
also serve as amplifiers of prejudice and stigmatizing attitudes toward OAT. Moreover, while 
other prisoners seem to be the source of most negative attitudes toward OAT, both physicians 
and family members also reinforce these notions, which may influence both prison- and 
community-based OAT expansion. Successful interventions, including peer-driven interventions 
(Broadhead et al., 2002; Broadhead et al., 1998), are likely to target primarily other prisoners, 
but comprehensively incorporate physicians, family and prison personnel. 
Our results underscore the negative impact of within-prison harassment, as bullying was 
higher and personal safety lower among those that actually accessed within-prison OAT.  In the 
presence of high levels of negative attitudes toward OAT by other prisoners, many prisoners do
not access the treatment.  We believe these interpersonal negative influences contribute to the 
unwillingness expressed by those not on methadone to consider enrolling in treatment post-
release, and the intention to discontinue it expressed by those who received methadone within 
prison. These effects undermine both within-prison and community OAT expansion efforts.  
Though not measured here, some of perpetuation of negative OAT attitudes and myths, 
alongside the increased harassment towards OAT patients, might be explained due to within-
prison instigated and perpetuated stigma and discrimination. Stigma is propagated to maintain 
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power and to reinforce social hierarchies, and in controlled prison settings, would likely be 
wielded for power-related purposes. OAT patients are likely to feel stigmatized or discriminated 
against in prison individually and/or as a group, and may become alienated, ostracized, and 
harassed by other prisoners (Kurzban & Leary, 2001). The role of stigma in interpersonal and 
inter-group violence is manifest here as bullying and concerns about personal safety (Schaller & 
Neuberg, 2008, 2012).   
Last, OAT implementation and enrollment in Moldovan prisons are influenced by 
ideological biases and myths that are largely formed, reinforced, and often magnified 
behaviorally in restricted prison settings. Future interventions that expand OAT in prisons should 
target individual-level myths and ideological prejudices, potentially through peer-driven 
interventions that harness the collection power of other prisoners or former prisoners who have 
had positive experiences with OAT, as well as the prisoner environment. 
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Figure 1.  A) Group differences for knowledge, attitudes, effectiveness, and 
myths about opioid agonist therapy (OST); B) Differences in Perceived 
Personal Safety and Bullying; C) The origin of the view that opioid agonist 
therapy is not a good treatment for opioid addiction.
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